EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial

Z. Zhang, X. Zheng, X. Cao, S. Simayi, H. Ge

International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S126-S127

DOI: 10.1016/j.ijrobp.2026.06.186 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von Z. Zhang und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Zhang, Z., Zheng, X., Cao, X., Simayi, S., & Ge, H. (2026). Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial. International Journal of Radiation Oncology*Biology*Physics, 126(1), S126-S127. https://doi.org/10.1016/j.ijrobp.2026.06.186

Vancouver

Zhang Z, Zheng X, Cao X, Simayi S, Ge H. Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S126-S127. doi:10.1016/j.ijrobp.2026.06.186

BibTeX
@article{Zhang2026,
  author = {Zhang, Z. and Zheng, X. and Cao, X. and Simayi, S. and Ge, H.},
  title = {Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  volume = {126},
  number = {1},
  pages = {S126--S127},
  doi = {10.1016/j.ijrobp.2026.06.186}
}
Kostenlos starten →